Faculty profile

Martha Louzada

Back to faculty

Cross-Appointed Associate ProfessorDepartment of Epidemiology and BiostatisticsWestern University

Martha Louzada

Cross-Appointed Associate Professor

Department of Epidemiology and Biostatistics

Schulich School of Medicine & Dentistry

Western University

London, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
20 publications in the last five years, latest in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

170

Citations

h-index

Collaborators

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Latest papers

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Lancet (London, England) · 2026
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
Clinical Lymphoma, Myeloma and Leukemia · 2026
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database
Clinical Lymphoma, Myeloma and Leukemia · 2026

All 31 publications

31 publications.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoé E, Gálvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG, SUCCESSOR-2 Trial Investigators

Lancet (London, England)2026

DOI: 10.1016/s0140-6736(26)01088-3 PMID: 42289183

Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Haider I, Leong DP, Shahid O, Louzada M, McCurdy A, Pond GR, Cameron R, Balitsky AK, Britto J, Aljama M

Clinical Lymphoma, Myeloma and Leukemia20261 citations

DOI: 10.1016/j.clml.2025.09.007

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Varghese J, Venner CP, Louzada M, Reece D, White D, Sharma S, Su J, Chu MP, Jimenez-Zepeda VH, McCurdy A

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.019

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Kaedbey R, Venner CP, Reece D, Hay K, Gul E, Su J, McCurdy A, Chu MP, Jimenez-Zepeda VH, Song K

Clinical Lymphoma, Myeloma and Leukemia2026

DOI: 10.1016/j.clml.2025.10.026

Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory's experience: Unsatisfactory assay reproducibility.

Cheong I, Liang C, Bhayana V, Stevic I, Louzada M, Chin-Yee I, Rutledge AC

Clinical biochemistry2025

DOI: 10.1016/j.clinbiochem.2025.110941 PMID: 40345317

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

McCurdy A, Gul E, Reece D, Chu MP, Jimenez-Zepeda VH, Louzada M, Song K, Mian H, Sebag M, White D

Clinical Lymphoma, Myeloma and Leukemia20252 citations

DOI: 10.1016/j.clml.2025.02.011

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Venner CP, Duggan P, Song K, Reece D, Sharma S, Su J, Jimenez-Zepeda VH, McCurdy A, Louzada M, Mian H

Transplantation and Cellular Therapy20249 citations

DOI: 10.1016/j.jtct.2024.06.030

Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)

Haider I, Leong DP, Louzada M, McCurdy A, Pond GR, Cameron R, Aljama M, Visram A, Wildes TM, Mian H

Leukemia and Lymphoma20248 citations

DOI: 10.1080/10428194.2024.2340052

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, Louzada M, Jimenez‐Zepeda VH, Mian H, Song K

eJHaem20245 citations

DOI: 10.1002/jha2.894

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study

Tanguay M, Roy J, Su J, Gul E, Reece D, Venner CP, White D, Chu MP, Jimenez‐Zepada VH, Song K

Cancer Medicine20241 citations

DOI: 10.1002/cam4.70332

Profile data last refreshed on November 9, 2025 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Martha Louzada

Research

Latest papers

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory's experience: Unsatisfactory assay reproducibility.

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database

Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)

Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study

Frequent collaborators

Arleigh McCurdy

Donna Reece

Michael Sebag

Hira Mian

Alissa Visram

Gregory Pond

Mohammed Aljama

Darryl Leong

Marc Carrier

Alejandro Lazo-Langner

Ivan Stevic

Christopher Venner

Tony Reiman

Sudeep Shivakumar

Amaris Karin Balitsky

Kevin Hay

Vicky Tagalakis

Peter Lawrence Gross